1-(tert-butylsulfanyl)-N,N-dimethylmethanamine | 1369272-98-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(tert-butylsulfanyl)-N,N-dimethylmethanamine
• 英文别名: 1-tert-butylsulfanyl-N,N-dimethylmethanamine
• CAS: 1369272-98-9
• 化学式: C₇H₁₇NS
• 分子量: 147.285
• InChiKey: ZNUWZUCWPRGGIB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  28.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  四甲基甲烷二胺 、 叔丁基硫醇 在 samarium(III) chloride hexahydrate 作用下， 反应 1.5h， 以97%的产率得到1-(tert-butylsulfanyl)-N,N-dimethylmethanamine
  参考文献：
  名称：

  N,N,N′,N′-tetramethylmethanediamine, efficient reagent for thioles aminomethylation

  摘要：

  Efficient method was developed for thiols aminomethylation using N,N,N',N'-tetra-methylmethanediamine in the presence of Sm and Fe salts. Aminosulfides were obtained in high yields and selectivity.

  DOI：

  10.1134/s1070428012020042

文献信息

• CHIRAL CONTROL
  申请人：WAVE LIFE SCIENCES PTE. LTD.

  公开号：US20150211006A1

  公开（公告）日：2015-07-30

  The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.

  本发明涉及手性控制的寡核苷酸、手性控制的寡核苷酸组合物以及其制备和使用方法。本发明特别涵盖了鉴定以前制备手性寡核苷酸方法中某些问题的来源，包括禁止制备完全手性控制的组合物，特别是包含多种寡核苷酸类型的组合物。在某些实施例中，本发明提供了手性控制的寡核苷酸组合物。在某些实施例中，本发明提供了制备手性控制的寡核苷酸和手性控制的寡核苷酸组合物的方法。
• Oligonucleotide compositions and methods thereof
  申请人：WAVE LIFE SCIENCES LTD.

  公开号：US10450568B2

  公开（公告）日：2019-10-22

  Among other things, the present disclosure relates to designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide altered splicing of a transcript. In some embodiments, provided oligonucleotide compositions have low toxicity. In some embodiments, provided oligonucleotide compositions provide improved protein binding profiles. In some embodiments, provided oligonucleotide compositions have improved delivery. In some embodiments, provided oligonucleotide compositions have improved uptake. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions.

  除其他外，本公开涉及设计的寡核苷酸、组合物及其方法。在一些实施方案中，所提供的寡核苷酸组合物能改变转录本的剪接。在一些实施方案中，所提供的寡核苷酸组合物具有低毒性。在一些实施方案中，所提供的寡核苷酸组合物提供了改进的蛋白质结合概况。在一些实施方案中，所提供的寡核苷酸组合物具有更好的传递性。在一些实施方案中，所提供的寡核苷酸组合物改善了吸收。在一些实施方案中，本公开提供了使用所提供的寡核苷酸组合物治疗疾病的方法。
• Chiral control
  申请人：WAVE LIFE SCIENCES LTD.

  公开号：US10590413B2

  公开（公告）日：2020-03-17

  The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.

  本发明涉及手性受控寡核苷酸、手性受控寡核苷酸组合物以及制作和使用方法。本发明具体包括确定先前制备手性寡核苷酸方法中某些问题的根源，包括禁止制备完全手性控制的组合物，特别是包含多种寡核苷酸类型的组合物的问题。在某些实施方案中，本发明提供了手性控制的寡核苷酸组合物。在一些实施方案中，本发明提供了制作手性控制寡核苷酸和手性控制寡核苷酸组合物的方法。
• Oligonucleotides, compositions and methods thereof
  申请人：WAVE LIFE SCIENCES LTD.

  公开号：US11013757B2

  公开（公告）日：2021-05-25

  The present disclosure pertains to the recognition that immune responses mediated by CpG oligonucleotides can be affected by the stereochemistry of modified internucleotidic linkages such as phosphorothioates. In some embodiments, the present disclosure relates to chirally controlled CpG oligonucleotide compositions comprising CpG oligonucleotides comprising multiple modified internucleotidic linkages such as phosphorothioate linkages, wherein the oligonucleotides comprise one or more CpG region motifs having defined stereochemistry patterns of chiral internucleotidic linkages. In some embodiments, CpG oligonucleotides comprising one or more CpG region motifs are capable of agonizing an immune response. In some embodiments, CpG oligonucleotides comprising one or more CpG region motifs are antagonistic. Methods for making and using chirally controlled CpG oligonucleotide compositions are also described. In some embodiments, no immune modulation is desired, and the present disclosure provides methods of identifying chirally controlled oligonucleotide compositions which have decreased immune modulation.

  本公开涉及这样一种认识，即 CpG 寡核苷酸介导的免疫反应可受硫代磷酸酯等修饰的核苷酸间连接的立体化学的影响。在一些实施方案中，本公开涉及手性控制的 CpG 寡核苷酸组合物，该组合物包含CpG 寡核苷酸，该CpG 寡核苷酸包含多个修饰的核苷酸间连接，如硫代磷酸酯连接，其中寡核苷酸包含一个或多个 CpG 区域基序，该 CpG 区域基序具有手性核苷酸间连接的确定立体化学模式。在一些实施方案中，包含一个或多个 CpG 区域基团的 CpG 寡核苷酸能够激动免疫反应。在某些实施方案中，包含一个或多个 CpG 区域基团的 CpG 寡核苷酸具有拮抗作用。还描述了制作和使用啁啾控制 CpG 寡核苷酸组合物的方法。在某些实施方案中，不需要免疫调节，本公开提供了确定免疫调节性降低的手性控制寡核苷酸组合物的方法。
• CHIRAL DESIGN
  申请人：WAVE LIFE SCIENCES LTD.

  公开号：US20170037399A1

  公开（公告）日：2017-02-09

  The present invention relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer.